← Human Trials & Peer-Reviewed Studies
Growth hormone treatment affects brain neurotransmitters and thyroxine [see comment].
Plain-language guide to PMID 8729530 (1996): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 8729530
- Journal
- Clinical endocrinology
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Burman P et al. (6 authors)
- DOI
- 10.1046/j.1365-2265.1996.617439.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
Binding sites specific for growth hormone have been identified in the brain, but the action of GH on the central nervous system is still poorly understood.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Twenty-four patients with documented GH deficiency acquired in adult life took part.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.
What Was Measured
Topics PubMed links to this paper include Aspartic Acid, Growth Disorders, Growth Hormone, Homovanillic Acid, Neurotransmitter Agents, Recombinant Proteins and Thyroid Hormones.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 1996 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.